How Does Qvar Work in the Body
Chemical Composition, Mechanism of Action & Metabolic Effects Explained
Key Takeaways: How Qvar Works
- Active ingredient: Beclometasone dipropionate, a synthetic corticosteroid.
- Prodrug activation: Converted in the lungs to the active metabolite beclometasone‑17‑monopropionate (B17MP).
- Primary action: Reduces airway inflammation, swelling, and irritation by suppressing pro‑inflammatory genes.
- Onset & duration: Clinical effect builds over days; full benefit after 1‑2 weeks regular use. Duration approximately 12 hours.
- Metabolism: Hydrolysed by esterases; excreted in faeces and urine. Low systemic bioavailability at recommended doses.
Qvar (beclometasone dipropionate) is a preventer inhaler that delivers a corticosteroid directly to the lungs to control inflammation. This deep dive explains its chemical structure, precise mechanism, and what happens to the drug inside your body.
Important Medical Advice
If you experience sudden wheezing or chest tightness immediately after using Qvar, stop using it and use your blue reliever inhaler. Contact your doctor urgently. Allergic reactions (swelling of lips, face, neck, skin rash) are rare but require immediate medical attention.
Chemical Composition & Molecular Structure
Qvar Autohaler contains beclometasone dipropionate, a diester prodrug of beclometasone. Each metered dose delivers either 50 micrograms or 100 micrograms of the active ingredient, together with the propellant HFA‑134a (norflurane) and a small amount of ethanol as a co‑solvent.
Structural Details
9‑chloro‑11β,17,21‑trihydroxy‑16β‑methylpregna‑1,4‑diene‑3,20‑dione 17,21‑dipropionate
A halogenated glucocorticoid ester. The two propionate groups enhance lipophilicity, improving lung tissue retention and providing prodrug characteristics.
Beclometasone‑17‑monopropionate
Formed by enzymatic hydrolysis of the 21‑propionate ester. B17MP has approximately 25‑fold higher affinity for the glucocorticoid receptor than the parent compound.
Key Pharmaceutical Properties
| Property | Beclometasone dipropionate | B17MP (active) |
|---|---|---|
| Lipophilicity (logP) | ~3.0 | ~2.5 |
| Receptor affinity (relative) | 1 | 25 |
| Protein binding | 87% | 94‑96% |
| Oral bioavailability | <1% (extensive first‑pass) | — |
🗒️ Pharmaceutical insight: The HFA‑134a propellant creates an extrafine aerosol, allowing a higher proportion of the dose to reach small airways compared to older CFC inhalers.
Mechanism of Action: Anti‑inflammatory Pathway
Qvar exerts its effect through a well‑established genomic pathway typical of inhaled corticosteroids.
- Prodrug activation: After inhalation, beclometasone dipropionate is deposited on airway surfaces. Esterases (primarily in lung epithelial lining fluid and cells) cleave the 21‑propionate group to yield beclometasone‑17‑monopropionate (B17MP).
- Receptor binding: B17MP diffuses across cell membranes and binds to glucocorticoid receptors (GR) in the cytoplasm of inflammatory cells (macrophages, eosinophils, lymphocytes) and structural cells (epithelial, smooth muscle).
- Nuclear translocation and gene modulation: The activated GR complex moves to the nucleus, where it suppresses transcription of pro‑inflammatory genes (e.g., cytokines IL‑4, IL‑5, IL‑13; chemokines; adhesion molecules) via transrepression. It also enhances transcription of anti‑inflammatory genes (lipocortin‑1, IL‑10, IκB‑α) via transactivation.
| Feature | Beclometasone dipropionate / B17MP |
|---|---|
| Onset of anti‑inflammatory effect | Hours to days (genomic) |
| Peak clinical improvement | 1‑2 weeks regular use |
| Duration of action | Approximately 12 hours (supports twice‑daily dosing) |
🗒️ Physiological insight: By reducing eosinophil infiltration and mucus hypersecretion, Qvar decreases airway hyperresponsiveness and prevents asthma exacerbations.
Absorption & Distribution (Pharmacokinetics)
Following inhalation from the Autohaler, approximately 30‑40% of the metered dose is deposited in the lungs. The remainder is swallowed and undergoes extensive first‑pass metabolism, resulting in negligible oral bioavailability.
Pulmonary absorption
Beclometasone dipropionate is rapidly absorbed from the lungs. It is immediately hydrolysed to B17MP, which reaches peak plasma concentration within 1‑2 hours. Systemic exposure is low at therapeutic doses.
Distribution
B17MP is highly lipophilic and widely distributed (volume of distribution ~20 L/kg). It is 94‑96% bound to plasma proteins. Animal studies show minimal passage across the blood‑brain barrier.
Metabolic Effects & Elimination
Beclometasone dipropionate is primarily activated and inactivated within the lung and liver. The main metabolic pathway involves hydrolysis by esterases to B17MP, which is further hydrolysed to beclometasone (inactive). A minor pathway involves CYP3A4‑mediated oxidation in the liver.
B17MP itself is cleared with a half‑life of about 2.7 hours. Metabolites are excreted predominantly in faeces (60%) via bile and in urine (40%) as conjugates. Less than 1% of an inhaled dose is recovered unchanged in urine.
⚠️ Metabolic caution: Severe hepatic impairment does not significantly affect B17MP kinetics because activation occurs mainly in the lung. However, high doses (>800 mcg/day) may cause measurable adrenal suppression.
Clinical Efficacy in Asthma Management
Qvar is indicated for regular maintenance treatment of asthma in adults and children aged 5 years and older. In clinical trials, twice‑daily dosing improved FEV₁, reduced daytime and night‑time symptoms, and decreased the need for rescue bronchodilators. The extrafine particle formulation enhances deposition in peripheral airways, offering efficacy at approximately half the daily dose of some conventional CFC‑beclometasone inhalers.
- Fixed‑dose maintenance: Typical starting dose for adults is 100‑200 mcg twice daily, adjusted according to response.
- Children (5‑11 years): 50‑100 mcg twice daily; growth should be monitored during prolonged treatment.
Regular use reduces exacerbation frequency and hospital admissions. Qvar is not a reliever; patients must continue to carry a short‑acting beta‑agonist (e.g., salbutamol) for acute symptoms.
Qvar FAQs
What are the most common side effects of Qvar?
Very common: oral thrush (white spots in mouth/throat). Common: hoarseness, sore throat. Rinsing your mouth with water after each use reduces these risks.
Can children use Qvar Autohaler?
Yes, Qvar is licensed for children aged 5 years and older. The dose is adjusted by age and response. Your doctor will monitor growth during prolonged treatment.
Does Qvar contain alcohol?
Yes, each dose contains a small amount of ethanol (<100 mg), which helps dissolve the drug. This is not enough to cause any noticeable effect.
What should I do if I miss a dose?
Take the missed dose as soon as you remember, unless it's nearly time for your next dose. Never double the dose. Then continue your regular schedule.
How do I clean the Autohaler device?
Wipe the mouthpiece with a clean dry tissue weekly. Do not wash or put any part of the inhaler in water, as moisture can damage the mechanism.
Need Qvar with Expert Guidance?
If you have asthma and think a preventer inhaler may help you, a UK‑registered doctor can assess your symptoms and provide a prescription online.
Secure Prescription & Next-Day Delivery
MHRA‑compliant | GPhC‑registered pharmacy | Discreet packaging | UK‑registered doctors
Start Asthma ConsultationRelated Qvar Guides
Clinical References & Sources
Medical Content Manager
Nabeel is a co-founder, and medical content manager of Chemist Doctor. He works closely with our medical team to ensure the information is accurate and up-to-date.
Medical Doctor
Dr. Feroz is a GMC-registered doctor and a medical reviewer at Chemist Doctor. He oversees acute condition and urgent care guidance.
Medical Director
Usman is a co-founder, and medical director of Chemist Doctor. He leads the organisation's strategic vision, bridging clinical and operational priorities.
Review Date: 8 March 2026
Next Review: 8 September 2026
Published on: 8 March 2026
Last Updated: 8 March 2026